Drug Profile
Research programme: geranylgeranylacetone trans-isomer - Coyote Pharmaceuticals
Alternative Names: CNS 101; CNS 102; CP-102; DDS-103; Geranylgeranylacetone trans-isomer; GGA trans-isomerLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator Coyote Pharmaceuticals
- Class Diterpenes; Small molecules
- Mechanism of Action Gene expression stimulants; Heat-shock protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis
- No development reported Glaucoma
Most Recent Events
- 21 Mar 2023 Preclinical development is ongoing for Alzheimer's disease and Amyotrophic lateral sclerosis on company's pipeline
- 28 Jul 2018 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic, Drops)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)